Diagnostic and prognostic role of matrix metalloproteases in cancer

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 9, 2008, Pages 1025-1039

  Vihinen, Pia ^a   Ala aho, Risto ^a,b   Kähäri, Veli Matti ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cancer; Diagnosis; Melanoma; MMP; Prognosis; Response

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; GELATINASE B; IMATINIB; IMMUNOMODULATING AGENT; INCYCLINIDE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SORAFENIB; STROMELYSIN; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CIRCULATION; CLINICAL EVALUATION; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESTROGEN ACTIVITY; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENOPAUSAL SYNDROME; METASTASIS; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RADIATION DOSE; RECTUM CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MELANOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR VOLUME; URINE;

EID: 77953428935     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.9.1025     Document Type: Review

References (150)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 2001;17:463-516 • Describes the basis of MMPs in cell biology.
2. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008;19:52-60 •• Comprehensive review about MMPs in tumor-host interactions.
3. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:163-75 •• Comprehensive review on MMPs in cancer.
4. Overall-CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-946
5. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; published online 24 December 2007, doi:10.1016/j.biocel.2007.12.006 •• Comprehensive new review about MMPs and their inhibitors.
6. Freije JM, Diez Itza I, Balbín M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269:16766-16773 (Pubitemid 24200439)
7. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-257 (Pubitemid 37363179)
8. Gronski TJ Jr, Martin RL, Kobayashi DK, et al. Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem 1997;272:12189-12194 (Pubitemid 27202803)
9. Shipley JM, Wesselschmidt RL, Kobayashi DK, et al. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996;93:3942-3946 (Pubitemid 26144227)
10. Ii M, Yamamoto H, Adachi Y, et al. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 2006;231:20-27 (Pubitemid 43063974)
11. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal a-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999;286:113-117 (Pubitemid 29484488)
12. Savinov AY, Remacle AG, Golubkov VS, et al. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res 2006;66:2716-2724
13. Seiki M. The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol 2002;14:624-632 (Pubitemid 35247747)
14. Impola U, Toriseva M, Suomela S, et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer 2003;103:709-716 (Pubitemid 36110225)
15. Väänänen A, Tjäderhane L, Eklund L, et al. Expression of collagen XVIII and MMP-20 in developing teeth and odontogenic tumors. Matrix Biol 2004;23:153-161 (Pubitemid 39037250)
16. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48:411-424 (Pubitemid 39360392)
17. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007;26:717-24 •• Comprehensive review about roles of MMPs in tumor suppression.
18. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8 •• Good review with new aspects about roles of different proteases in tumor suppression.
19. McCawley LJ, Crawford HC, King LE Jr, et al. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004;64:6965-6972 (Pubitemid 39331006)
20. Witty JP, Lempka T, Coffey RJ Jr, Matrisian LM. Decreased tumor formation in 7,12-dimethylbenzanthracene.treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 1995;55:1401-1406
21. Kerkelä E, Ala-aho R, Klemi P, et al. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol 2002;198:258-269 (Pubitemid 35243885)
22. Montel V, Kleeman J, Agarwal D, et al. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res 2004;64:1687-1694 (Pubitemid 38428690)
23. Vihinen P, Koskivuo I, Syrjänen K, et al. Serum MMP-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res 2008;18:268-273
24. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-490
25. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744 (Pubitemid 30768157)
26. Dong Z, Kumar R, Yang X, Fidler IJ. Macropahge-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinima. Cell 1997;88:801-810 (Pubitemid 27164268)
27. Hurst NG, Stocken DD, Wilson S, et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007;97:971-977 (Pubitemid 47519304)
28. Smith ER, Manfredi M, Scott RM, et al. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery 2007;60:E1148-9 (Pubitemid 46849869)
29. Kuhlmann KF, van Till JW, Boermeester MA, et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:886-891 (Pubitemid 46910086)
30. Määttä M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Matrix metalloproteinase-2(MMP-2) and-9(MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumors. Anticancer Res 2007;27:2753-2758 (Pubitemid 47227993)
31. Somiari SB, Somiari RI, Heckman CM, et al. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006;119:1403-1411 (Pubitemid 44258818)
32. Aung PP, Oue N, Mitani Y, et al. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 2006;25:2546-2557
33. Eissa S, Ali-Labib R, Swellam M, et al. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 2007;52:1388-1396 (Pubitemid 47445978)
34. Tan SY, Wang JY, Shen L, et al. Relationship between preoperative staging by endoscopic ultrasonography and MMP-9 expression in gastric carcinoma. World J Gastroenterol 2007;13:2108-2112 (Pubitemid 46795851)
35. Kim HJ, Lee JY, Kim SH, et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 2007;157:319-324 (Pubitemid 47083868)
36. Holtkamp N, Atallah I, Okuducu AF, et al. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 2007;9:671-677 (Pubitemid 47328086)
37. Sillanpää S, Anttila M, Suhonen K, et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 2007;28:280-289 (Pubitemid 350165834)
38. Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002;69:205-212 (Pubitemid 35448125)
39. Gorrin-Rivas, Arii S, Furutani M, et al. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology 1998;28:986-993 (Pubitemid 28450259)
40. Scorilas A, Karameris A, Arnogiannaki R, et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001;84:1488-1496 (Pubitemid 32579341)
41. Decock J, Hendrickx W, Drijkoningen M, et al. Matrix metalloproteinase expression patterns in luminal A type breast carcinomas. Dis Markers 2007;23:189-196 (Pubitemid 46868410)
42. Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12 [abstract LBA4]. J Clin Oncol 2008;26(Suppl):1006S
43. Vihinen P, Ala-aho R, Kähäri V-M. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5:203-220 (Pubitemid 40694861)
44. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 2005;11:7311-7321 (Pubitemid 41507689)
45. Mylona E, Nomikos A, Magkou C, et al. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 2007;50:338-347 (Pubitemid 46169418)
46. Jiang WG, Davies G, Martin TA, et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 2006;17:583-590
47. Swellam M, Arab LR, Bushnak HA. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer. IUBMB Life 2007;59:394-401 (Pubitemid 47027113)
48. Chenard MP, O'Siorain L, Shening S, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996;69:448-451 (Pubitemid 27050520)
49. Hirvonen R, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T (1-2)N0 breast carcinoma. Breast Cancer Res Treat 2003;77:85-91
50. Rahko E, Jukkola A, Melkko J, et al. Matrix metalloproteinase-9(MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Res 2004;24:4247-4253 (Pubitemid 40468736)
51. Têtu B, Brisson J, Wang CS, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006;8:R28
52. Djonov V, Cresto N, Aebersold DM, et al. Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Oncol 2002;21:25-30
53. Leppä S, Saarto T, Vehmanen I, et al. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004;10:1057-1063 (Pubitemid 38198907)
54. Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10:7621-7628 (Pubitemid 39557525)
55. Hughes S, Agbaje O, Bowen RL, et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res 2007;13:6673-6680 (Pubitemid 350206803)
56. Blot E, Chen W, Vasse M, et al. Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness. Br J Cancer 2003;88:1207-1212 (Pubitemid 36606334)
57. González LO, Pidal I, Junquera S, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 2007;97:957-963 (Pubitemid 47519308)
58. Lee S, Desai KK, Iczkowski KA, et al. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res 2006;16:750-758 (Pubitemid 44395435)
59. Cao J, Chiarelli C, Richman O, et al. Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem 2008;283:6232-6240
60. Wood M, Fudge K, Mohler JL, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-258
61. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005;33:44-50 (Pubitemid 40487192)
62. Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006;4:437-447 (Pubitemid 44197039)
63. König JE, Senge T, Allhoff EP, König W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004;58:121-129 (Pubitemid 38160899)
64. Wilson MJ, Woodson M, Wiehr C, et al. Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp Mol Pathol 2004;77:7-17 (Pubitemid 38822922)
65. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007;67:774-781 (Pubitemid 46709446)
66. Pang ST, Flores-Morales A, Skoog L, et al. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol Rep 2004;11:1187-1192
67. Jennbacken K, Gustavsson H, Welén K, et al. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 2006;66:1631-1640 (Pubitemid 44646354)
68. Assikis VJ, Do KA, Wen S, et al. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 2004;10:6770-6778 (Pubitemid 39383025)
69. Bonfil RD, Dong Z, Trindade Filho JC, et al. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 2007;170:2100-2111 (Pubitemid 47339282)
70. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7:485-496 (Pubitemid 40719131)
71. Dong Z, Bonfil RD, Chinni S, et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005;166:1173-1186 (Pubitemid 40524441)
72. Golshayan AR, Brick AJ, Choueiri TK. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 2008;4:85-92
73. Blouw B, Haase VH, Song H, et al. Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene. Oncogene 2007;26:4531-4540 (Pubitemid 47037048)
74. Hong X, Jiang F, Kalkanis SN, et al. Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion. J Exp Ther Oncol 2007;6:219-229 (Pubitemid 46789722)
75. Kawata N, Nagane Y, Hirakata H, et al. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 2007;69:1049-1053 (Pubitemid 46891585)
76. Atkinson JM, Pennington CJ, Martin SW, et al. Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer 2007;43:1764-1771 (Pubitemid 47042378)
77. Delebecq TJ, Porte H, Zerimech F, et al. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res 2000;6:1086-1092 (Pubitemid 30159371)
78. Tamura M, Oda M, Matsumoto I, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004;11:928-933 (Pubitemid 40486679)
79. Maurel J, Nadal C, Garcia-Albeniz X, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007;121:1066-1071
80. Soreide K, Janssen EA, Körner E, Baak JP. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol 2006;209:147-156 (Pubitemid 43805409)
81. Ishii Y, Nakasato Y, Kobayashi S, et al. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 2003;22:461-470 (Pubitemid 37205405)
82. Hsiang CY, Wu SL, Chen JC, et al. Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-kappaB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: Association with the invasive potential. Toxicol Lett 2007;171:78-86 (Pubitemid 46990670)
83. Sier CF, Kubben FL, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-417 (Pubitemid 26254571)
84. Gao ZL, Zhang C, Du GY, Lu ZJ. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology 2007;54:1591-1595 (Pubitemid 47203480)
85. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004;23:101-117 (Pubitemid 38221598)
86. Tsareva SA, Moriggl R, Corvinus FM, et al. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 2007;9:279-291 (Pubitemid 46608295)
87. Cho YB, Lee WY, Song SY, et al. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 2007;38:1603-1610 (Pubitemid 47589089)
88. Bendardaf R, Lamlum H, Vihinen P, et al. Low collagenase-1(MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. Oncology 2003;65:337-346 (Pubitemid 38064946)
89. Perigny M, Bairati I, Harvey I, et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 2008;129:226-231 (Pubitemid 352029312)
90. Wong KK, Lu KH, Malpica A, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007;26:404-409 (Pubitemid 47476325)
91. Kamat AA, Fletcher M, Gruman LM, et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006;12:1707-1714
92. Stadlmann S, Pollheimer J, Moser PL, et al. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur J Cancer 2003;39:2499-2505 (Pubitemid 37340163)
93. Shield K, Riley C, Quinn MA, et al. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 2007;6:11
94. Sillanpää SM, Anttila MA, Voutilainen KA, et al. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer 2006;119:1792-1799 (Pubitemid 44356835)
95. Belkaid A, Fortier S, Cao J, Annabi B. Necrosis induction in glioblastoma cells reveals a new "bioswitch" function for the MT1-MMP/G6PT signaling axis in proMMP-2 activation versus cell death decision. Neoplasia 2007;9:332-340
96. Lee H, Sodek KL, Hwang Q, et al. Phagocytosis of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP. Biochem Soc Trans 2007;35:704-706 (Pubitemid 47310348)
97. Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007;9:893-904 •• Important paper on the role of MMPs in cancer cell invasion mechanisms.
98. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 2007;67:4227-4235 (Pubitemid 46815069)
99. Liu SY, Liu YC, Huang WT, et al. Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas. J Oral Pathol Med 2007;36:430-435 (Pubitemid 47037899)
100. El Houda Agueznay N, Badoual C, Hans S, et al. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships. Clin Exp Immunol 2007;150:114-123 (Pubitemid 47383297)
101. Culhaci N, Metin K, Copcu E, Dikicioglu E. Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer 2004;4:42 (Pubitemid 40180244)
102. Luukkaa M, Vihinen P, Kronqvist P, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 2006;28:225-234 (Pubitemid 43269889)
103. Kuivanen T, Ahokas K, Virolainen S, et al. MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. Virchows Arch 2005;447:954-960 (Pubitemid 41719550)
104. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005;87:307-14 • Comprehensive review about MMPs in melanoma.
105. Kawasaki K, Kawakami T, Watabe H, et al. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma. Br J Dermatol 2007;156:613-619 (Pubitemid 46452340)
106. Giambernandi TA, Sakaguschi AY, Gluhak J, et al. Neutrophil collagenase (MMP-8) is expressed during early development in neural crest cells as well as in adult melanoma cells. Matrix Biol 2001;20:577-587 (Pubitemid 33109105)
107. Hoek K. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 2007;20:466-484 (Pubitemid 47568833)
108. Agarwal D, Goodison S, Nicholson B, et al. Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 2003;71:114-125 (Pubitemid 36359680)
109. Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res 2007;67:10849-10858 (Pubitemid 350145914)
110. Nikkola J, Vihinen P, Vlaykova T, et al. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97:432-438 (Pubitemid 34027800)
111. Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005;11:5158-5166 (Pubitemid 41003701)
112. Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T. Gelatinase A and B (MMP-2, MMP-9) in leukaemia: MMP-2 may indicate a good prognosis in AML. Anticancer Res 1999;19:4395-4400 (Pubitemid 30042796)
113. Lin LI, Lin DT, Chang CJ, et al. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patinets with acute myelogenous leukaemia. Br J Haematol 2002;117:835-841 (Pubitemid 34639244)
114. Molica S, Vitelli G, Levato D, et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 2003;70:373-378 (Pubitemid 36713932)
115. Mannello F. Serum or plasma samples?: the "Cinderella" role of blood collection procedures preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, harpering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008;28:611-614
116. Chapman PB, Shah G, Brady M, Coit DG. Phase II trial of neoadjuvant temozolomide in melanoma patients. Pigment Cell Res 2007;20:525
117. Chapman PB, Shah G, Brady M, Coit DG: Phase II Trial of neoadjuvant temozolomide in melanoma patients. Presentation in the 4th International Melanoma Congress; 2007; New York, USA
118. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520 (Pubitemid 39315318)
119. Li Y, Kucuk O, Hussain M, et al. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006;66:4816-4825
120. Van Roy M, Van Lint P, Van Laere I, et al. Involvement of specific matrix metalloproteinases during tumor necrosis factor/IFNgamma-based cancer therapy in mice. Mol Cancer Ther 2007;6:2563-2571 (Pubitemid 47480422)
121. Ahn KS, Bae E, Jeon SS, et al. Microenvironment effects on promoting upregulation of matrix metalloproteinases in Bcl-2-overexpressing renal cell carcinoma as a response to doxorubicin treatment inducing the production of metastasis. Tumour Biol 2007;28:181-188 (Pubitemid 46976005)
122. Skogseth H, Larsson E, Halgunset J. The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase. APMIS 2006;114:61-66 (Pubitemid 43356836)
123. Stahtea XN, Roussidis AE, Kanakis I, et al. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int J Cancer 2007;121:2808-2814 (Pubitemid 350136431)
124. Rosanò L, Di Castro V, Spinella F, et al. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 2007;6:2003-2011 (Pubitemid 47052490)
125. Zucker S, Wang M, Sparano JA, et al. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. Clin Breast Cancer 2006;6:525-529
126. Leppä S, Saarto T, Vehmanen L, et al. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat 2005;90:117-125 (Pubitemid 40568895)
127. Nieder C, Wiedenmann N, Andratschke N, Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006;32:348-364 (Pubitemid 44063875)
128. Ridgway PF, Ziprin P, Alkhamesi N, et al. Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro. J Surg Res 2005;124:180-186 (Pubitemid 40463716)
129. Wild-Bode C, Weller M, Rimner A, et al. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001;61:2744-2750 (Pubitemid 32685864)
130. Yang K, Palm J, König J, et al. Matrix-metallo-proteinases and their tissue inhibitors in radiation-induced lung injury. Int J Radiat Biol 2007;83:665-676 (Pubitemid 47345865)
131. Paquette B, Baptiste C, Therriault H, et al. In vitro irradiation of basement membrane enhances the invasiveness of breast cancer cells. Br J Cancer 2007;97:1505-1512
132. Qian LW, Mizumoto K, Urashima T, et al. Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix
133. Kumar A, Collins H, Van Tam J, et al. Effect of preoperative radiotherapy on matrilysin gene expression in rectal cancer. Eur J Cancer 2002;38:505-510 (Pubitemid 34185389)
134. Angenete E, Langenskiöld M, Falk P, Ivarsson ML. Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation. Int J Colorectal Dis 2007;22:667-674 (Pubitemid 47097038)
135. Unsal Kilic D, Uner A, Akyurek N, et al. Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;67:196-203 (Pubitemid 44959478)
136. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004;22:499-506 (Pubitemid 41079780)
137. Nakamura JL, Haas-Kogan DA, Pieper RO. Glioma invasiveness responds variably to irradiation in a co-culture model. Int J Radiat Oncol Biol Phys 2007;69:880-886 (Pubitemid 47418417)
138. Levin VA, Phuphanich S, Yung WK, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006;78:295-302 (Pubitemid 44018824)
139. Nasr HB, Mestiri S, Chahed K, et al. Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. Clin Chim Acta 2007;348:57-63 (Pubitemid 47247410)
140. Lu Z, Cao Y, Wang Y, et al. Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China. J Neurooncol 2007;85:65-73
141. Przybylowska K, Zielinska J, Zadrozny M, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 2004;23:121-125 (Pubitemid 38552606)
142. Six L, Grimm C, Leodolter S, et al. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol 2006;100:506-510 (Pubitemid 43246866)
143. Lai HC, Chu M, Lin YW, et al. Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol 2005;96:314-319 (Pubitemid 40127127)
144. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 2008;65:68-72
145. Kubben FJ, Sier CR, Meijer MJ, et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 1996;95:744-751
146. Vairaktaris E, Serefoglou Z, Yapijakis C, et al. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res 2007;27:2493-2498 (Pubitemid 47228094)
147. Xing LL, Wang ZN, Jiang L, et al. Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol 2007;13:4626-4629 (Pubitemid 47455246)
148. Tu HF, Wu CH, Kao SY, et al. Functional-1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 2007;36:409-414 (Pubitemid 47037907)
149. Kader AK, Liu J, Shao L, et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 2007;13:2614-2620 (Pubitemid 46788027)
150. Vairaktaris E, Yapijakis C, Nkenke E, et al. A metalloproteinase-13 polymorphism affecting its gene expression is associated with advanced stages of oral cancer. Anticancer Res 2007;27(6B):4027-4030